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Abstract
Background
Therapeutic options are limited in secondary progressive multiple sclerosis (SPMS). Open-
label studies suggested efficacy of monthly IV cyclophosphamide (CPM) without induction
for delaying progression but no randomized trial was conducted so far.
Objective
To compare CPM to methylprednisolone (MP) in SPMS.
Methods
Randomized, double-blind clinical trial on two parallel groups. Patient with SPMS, with a
documented worsening of the Expanded Disability Status Scale (EDSS) score during the
last year and an EDSS score between 40 and 65 were recruited and received one intrave-
nous infusion of treatment (CPM: 750 mg /m2 body surface area—MP: 1g) every four weeks
for one year, and every eight weeks for the second year. The primary endpoint was the time
to EDSS deterioration, when confirmed sixteen weeks later, analyzed using a Cox model.
Results
Due to recruitment difficulties, the study was terminated prematurely after 138 patients were
included (CPM, n = 72; MP, n = 66). In the CPM group, 33 patients stopped treatment
PLOS ONE | DOI:10.1371/journal.pone.0168834 January 3, 2017 1 / 15
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Brochet B, Deloire MSA, Perez P, Loock
T, Baschet L, Debouverie M, et al. (2017) Double-
Blind Controlled Randomized Trial of
Cyclophosphamide versus Methylprednisolone in
Secondary Progressive Multiple Sclerosis. PLoS
ONE 12(1): e0168834. doi:10.1371/journal.
pone.0168834
Editor: Tim Friede, University Medical Center
Gottingen, GERMANY
Received: July 1, 2016
Accepted: December 4, 2016
Published: January 3, 2017
Copyright: © 2017 Brochet et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: There is a legal
restriction for transferring the dataset. The
database of the trial was declared to and authorized
by the French data protection authority (CNIL) in
May 2004, but no transfer of data was planned at
that time. This concerns the transfer of individual
patient data. Data however is available upon
request. Interested researchers can contact Dr.
Paul Perez (paul.perez@isped.u-bordeaux2.fr) at
the University Hospital of Bordeaux.
prematurely, mainly due to tolerability, compared with 22 in the MP group. Primary endpoint:
the hazard ratio for EDSS deterioration in the CPM in comparison with the MP group was
0.61 [95% CI: 031–122](p = 016). According to the secondary multistate model analysis,
patients in the CPM group were 2.2 times more likely ([114–4.29]; p = 0.02) to discontinue
treatment than those in the MP group and 2.7 times less likely (HR = 0.37, 95% CI: 0.17–
0.84; p = 0.02) to experience disability progression when they did not stop treatment prema-
turely. Safety profile was as expected.
Conclusion
Although the primary end-point was negative, secondary analysis suggested that CPM
decreases the risk of progression in SPMS, but its use may be limited by low tolerability.
Trial Registration
Clinicaltrials.gov NCT00241254
Introduction
Therapeutic options for multiple sclerosis (MS) have dramatically increased in the past 20
years. However, such treatments primarily benefit patients with relapsing-remitting MS. Until
recently, only a few drugs have been tested in randomized controlled trials (RCTs) in progres-
sive MS (PMS), including Interferon-β [1–8]. The inconsistent results of these trials led to the
interpretation that secondary PMS (SPMS) may not be affected by immunological treatment
because the main pathological substratum of disability progression is neurodegeneration [9].
However, recent pathological studies have suggested that inflammation still plays a role in
SPMS and is associated with axonal injury [10–12]. Meningeal inflammation has been
described in SPMS and it has been suggested that it may play a major role in the development
of disability [13]. The inflammatory process observed in SPMS has been described as being
confined to the brain or the meninges, with limited trafficking of blood-derived immune cells
across the blood-brain barrier [10,13]. Therefore their inability to reach the central nervous
system may explain the failure of most drugs in SPMS. Immunosuppressants have been pro-
posed to treat PMS for many years [14,15]. Methotrexate [14] and mitoxantrone [15] have
been studied in RCTs in patients with various clinical phenotypes including PMS, suggesting
that immunosuppressive therapy could be useful in PMS, especially in patients showing evi-
dence of active inflammation (relapses or lesion activity on magnetic resonance imaging) [13].
The Mitoxantrone trial included 50% of SPMS patients and showed a positive effect of mitox-
antrone over placebo on the primary outcome which was a a multivariate analysis of five clini-
cal measures [15]. Cyclophosphamide (CPM), a nitrogen mustard alkylating agent, is able to
cross the blood-brain-barrier and has been considered as a treatment for many years [16]. Sev-
eral RCTs of intravenous (IV) CPM have been conducted in PMS, using an induction regimen
without maintenance therapy, with contradictory results [17–19]. The absence of maintenance
therapy could explain the lack of sustained effect [20]. Repeated administration of CPM has
also been proposed [20] supporting the use of maintenance therapy. Based on these results
monthly administration of IV CPM has been used in several centres and encouraging results
regarding efficacy and an acceptable safety profile have been reported in a large retrospective
study [21]. To date, no RCT has studied the effect of IV pulses of CPM in SPMS without an
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induction regimen. The objectives of the present randomized controlled trial were to assess
the efficacy of CPM in delaying disability progression, and the safety of IV pulses of CPM
administered over two years, relative to IV pulses of methylprednisolone (MP). Considering
that MP pulse therapy was which is frequently used in centres in France to treat SPMS after
promising results emerged from a pilot study [22], Tthe steering committee considered that
the use of this comparator will increase the feasibility of the trial.
Patients and Methods
Study design and patients
The PROgressive MultiplE Sclerosis Study (PROMESS) study was a two parallel group double-
blind RCT. Eligible patients were men and women, 18–65 years of age, with SPMS [23,24],
enrolled from 27 French Neurology departments. SPMS was defined by a gradual progression
of disability for at least six months and less than four years. Additionally, a documented wors-
ening on the Expanded Disability Status Scale (EDSS) [25] of at least 05 points in the last 12
months that was not due to a relapse and a reduction in walking distance in the past year were
required for selecting patients with active progression. The baseline EDSS score had to be
between 40 and 65, inclusive. Key exclusion criteria included any contraindications to the
study drugs. An independent committee reviewed issues relating to safety. The study was coor-
dinated by the coordinating center (CC) based at the University Hospital (CHU), Bordeaux.
The study was conducted in accordance with the international guidelines for Good Clinical
Practice and the principles of the Declaration of Helsinki. Patients provided written informed
consent. The study was approved by the regional ethics committee (“CPP Sud-Ouest Outre-
Mer”, N˚2005/09) and registered on Clinicaltrials.gov: NCT00241254.
Randomization and masking
Patients were allocated to receive either CPM or MP using a web-based secured system accord-
ing to a randomization list generated and kept confidential by the statistician of the Clinical
Trials Unit (CTU, CHU Bordeaux) using SAS 91©. Randomization, with a 1:1 ratio, was strati-
fied by centre, with blocks of size four for small sites and size six for others. All study personnel
were blinded to group allocation, including the neurologists and nurses administrating the
treatments. Because the study drugs have potential adverse effects that may make patients and
clinicians guess the treatment received, outcome assessments were performed by an evaluating
neurologist (EN); the treating neurologist (TN) evaluated the clinical state, safety and tolerabil-
ity. Study drugs were prepared in hospital pharmacies in similar infusion vials that precluded
the identification of the group assignment by patients and study personnel.
Treatments
Patients received either IV CPM (750 mg /m2 body surface area) or IV MP (1 g), administered
every four weeks for one year and every eight weeks during the second year. The procedures
for the administration of the study drugs were similar in both groups. All patients received a
5% glucose serum infusion spanning eight hours, with the study drug being infused during the
first three hours, followed by serum alone for five hours. The purpose of this was to reduce the
risk of toxic cystitis, which was expected with CPM treatment only. To reduce the incidence of
gastrointestinal adverse events related to infusion, all patients received three IV injections of
either an anti-emetic treatment (ondansetron, 8 mg) in the CPM group or a placebo in the MP
group, in a double-blind manner. Three days before each admission all patients underwent
laboratory testing to count peripheral blood cells, analyze sodium, potassium, and hepatic
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enzymes, and test renal function. The laboratory sent the results to a prescribing physician
(PP) located at the CC who was not blinded to treatment allocation. Depending if the results
were in the range of pre-defined normal values or not, the PP sent the prescription to the hos-
pital pharmacist in the clinical centre, either with a standard, or with an adapted study drug
dosage according to a pre-defined algorithm.
According to the TN’s decision, patients with relapses could receive IV MP one gram for
five days. Relapses were defined as new or worsening neurological symptoms attributable to
multiple sclerosis, lasting at least 48 h, without pyrexia, after at least 30 days of clinical stability
with an EDSS increase of at least 0.5 points or an FSS increase of 1 point.
Endpoints
The primary outcome was the time to sustained accumulation of disability over 16 weeks,
defined as an increase from baseline of at least one EDSS point when the baseline EDSS was 4
or 45, or at least 05 points if the baseline EDSS was between 50 and 65, confirmed 16 weeks
later. This 16-weeks interval was chosen because patients went at the clinic every two months
during the second year for treatment. In order to limit inter-rater variability in EDSS grading,
the ENs were asked to perform a standardized neurological examination, to grade Functional
Status Scores (FSS) according to an adapted French version of the EDSS [25] and to objectively
measure the patient’s walking distance up to 500 meters according to their functional ability.
The results were sent to the CC, where the EDSS scores were established according to a pre-
defined algorithm [25].
Key secondary outcomes were the proportion of patients with sustained EDSS progression
at 2 years, MS Functional Composite (MSFC) z scores progression, the relapse rate, and the
proportion of relapse-free patients. When patients refused to go on with their follow-up visits
during the course of the trial, efforts were made for obtaining the outcome criteria at their
two-year visit. Treatment failure was defined as either EDSS progression at 2 years or missing
data on EDSS at 2 years due to early discontinuation of treatment because of adverse events.
Adverse events were collected according to a standardized method using the EudraVigilance
database.
Sample size
The sample size calculation was based on a Log-Rank test, assuming an expected proportion of
patients without EDSS progression at two years of 75% in the CPM group and 60% in the MP
group. The type I error (two-sided) was fixed at 5% and the chosen power was 80%. Under
these assumptions, 155 patients had to be included in each group (nQuery V 7.0). For taking
into account 5% of drop outs and possible protocol deviations, 360 patients in total were
planned to be recruited.
Study enrolment and retention of patients were slower than expected. As a result, in July
2009 enrolment was terminated at 138 patients.
Statistical analysis
For the main analysis of the primary endpoint (time to sustained accumulation of disability
over 16 weeks), an intention-to-treat strategy was employed. A survival frailty model that con-
sidered sites as random effects was first fitted. If the variance of the random effect was found to
be negligible, a Cox model was fitted with and without adjustment [26]. Adjustment covariates
were the presence of relapses in the year preceding the trial and the disease duration. The
interaction between treatment effect and relapses was tested. The time to confirmed EDSS pro-
gression was censored whenever patients stopped follow-up before progression.
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Due to the high number of treatment discontinuations the statistical analysis plan was
revised and validated before the database freeze and treatment unblinding, including a pre-
planned secondary analysis jointly modelling delays of early discontinuation of treatment and
of confirmed EDSS progression, using a multistate model of the “illness-death” type [27,28]
with and without adjustment, which was fit using the SmoothHazard R package [29].
Secondary endpoints were analyzed using logistic regression for dichotomous outcomes,
linear regression for continuous outcomes. Comparisons were adjusted on covariates with
sites as random effects when possible.
The R package msm, and more complex models with disability progression occurrence
made possible after treatment discontinuation, were used as robustness analyses for the main
multistate model [28–29]. In the analyses of secondary endpoints, missing data due to early
discontinuation of treatment because of adverse events were considered treatment failures as
were progressions. Based upon the sample size that there was little power to test the interaction
effect. All analyses were performed by the biostatistician from the CTU. Except for multistate
models, SAS 921 was used. Type I error was fixed at 5%.
Results
Patient characteristics
One hundred and forty-eight patients were included between 11/16/2005 and 07/16/2009,
when recruitment closed. Due to a low recruitment rate, it was decided to stop the study at this
stage. Seventy-two patients were randomly allocated to receive CPM and 66 to receive MP
treatment. Table 1 summarizes the baseline characteristics of the patients.
Fifty—five patients overall discontinued treatment, more frequently in the CPM than the
MP arm (Fig 1).
Among the 33 patients who discontinued treatment in the CPM arm, 20 did so because of
adverse events, compared to five out of 22 in the MP group. A high proportion of patients dis-
continuing treatment also stopped coming to follow-up visits (29 out of 33 in the CPM group
and 18 out of 20 in the MP group), generating missing data on the primary outcome. The time
to possible disability progression was therefore not possible to determine for those patients
who were censored in the primary analysis. The mean follow-up duration was 87 weeks (Stan-
dard deviation (SD) = 37) in the CPM group and 95 weeks (SD = 26) in the MP group
(p = 0.15).
Table 1. Baseline characteristics, PROMESS trial, France.
CPM (n = 72) MP (n = 66)
Age* 486 (90) 468 (90)
Gender (% women) 62.0 68.2
Disease duration (y)* 139 (73) 11.9 (56)
Secondary progressive phase duration (y)* 1.9 (10) 19 (10)
% with relapse in the previous year 330 379
% with relapse in the SP phase 408 500
Median EDSS [Q1-Q3] 5 [4–6] 5 [4–6]
MSFC z scores* -05 (07) -03 (08)
* = mean (standard deviation);
CPM = Cyclophosphamide; MP = Methylprednisolone; EDSS = Expanded Disability Status Scale;
MSFC = Multiple Sclerosis Functional Composite.
doi:10.1371/journal.pone.0168834.t001
Cyclophosphamide in Secondary Progressive Multiple Sclerosis
PLOS ONE | DOI:10.1371/journal.pone.0168834 January 3, 2017 5 / 15
Outcomes
Primary endpoint. The proportion of patients with sustained EDSS progression at 2 years
was 181% (n = 13) in the CPM group and 318% (n = 21) in the MP group (p = 006), but a
high proportion of patients could not be assessed for this outcome, more frequently in the
CPM group than in the MP group (Table 2).
According to the Cox model, where those patients were censored at the time of stopping
their follow-up, the adjusted hazard ratio of progression was 0.61 (95% CI: 0.31–1.22) for the
CPM group in comparison with the MP group (p = 0.16). The treatment effect was not differ-
ent depending on the presence of relapses during the 12 months before inclusion: the interac-
tion was not statistically significant (p = 0.74) and the inclusion of relapses in the Cox model
did not change efficacy results.
Secondary analyses. The multistate model assesses the risk for a patient to change from a
state to another (from the state at inclusion to either EDSS deterioration or treatment discon-
tinuation). According to this analysis, patients in the CPM group were 2.2 times more likely to
discontinue their treatment as compared to the MP group (HR = 2.21; 95% CI: 1.14–4.29), but
they were 2.7 times more likely not to experience sustained EDSS progression (HR = 0.37; 95%
CI: 0.17–0.84) (Fig 2). The two transition HRs were statistically significant (p = 0.019 and
p = 0.018) showing that patients had more chance to change from “on treatment” state to “dis-
continued treatment” state and from “stable EDSS” state to “deteriorated EDSS” state). In
Fig 1. Flow chart of the PROMESS trial, France.
doi:10.1371/journal.pone.0168834.g001
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Table 2. Secondary clinical endpoints, PROMESS trial, France.
CPM (n = 72) n (%) MP (n = 66) n (%) p value*
EDSS during follow-up 0.21
sustained EDSS progression 13 (181) 21 (318)
no sustained EDSS progression during 2 years 36 (500) 34 (515)
loss to follow-up before progression 23 (319) 11 (167)
Two-year treatment failure** 0.59
Yes 29 (468) 26 (419)
No 33 (532) 36 (581)
missing data 10 4
Number of relapses during follow-up 0.17
0 53 (736) 39 (591)
1 12 (167) 15 (227)
>1 7 (97) 12 (182)
Annualized relapse rate 0.3 (0.6) 0.4 (0.5) 0.12
* Chi-square test
** Failure was defined as EDSS progression or discontinuation of treatment because of an adverse event;
CPM = Cyclophosphamide; MP = Methylprednisolone; EDSS = Expanded Disability Status Scale.
doi:10.1371/journal.pone.0168834.t002
Fig 2. Multistate “illness-death” analysis scheme and results. This figure describes the risks of transition
undergone by trial participants between three states. Of special interest are transitions from the initial state (at
inclusion) to either EDSS deterioration (primary outcome) or early treatment discontinuation. Risks are
expressed as hazard ratios (HR) (and their 95% confidence intervals), i.e., the risk of transition for the
experimental (CPM) group relative to the control (MP) group of patients. When the HR is < 1, the risk of
transition is decreased (treatment efficacy), and when it is > 1, the risk of transition is increased.
doi:10.1371/journal.pone.0168834.g002
Cyclophosphamide in Secondary Progressive Multiple Sclerosis
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other words patients not discontinuing treatment were more likely to benefit from CPM than
MP.
From the initial state (at inclusion), patients may evolve to EDSS deterioration or early
treatment stopping. HR is the point estimate of the Hazard Ratio of transition from one state
to the other for the CPM group in comparison to the MP group; the 95% confidence interval
of HR is given between brackets. The number of patients is given for each transition in each
group.
As a sensitivity analysis, we estimated the proportion of patients with treatment failure at
two years in the two groups (failure was defined as either EDSS progression or early discontin-
uation of treatment due to an adverse event). Treatment failure occurred in 468% of the
patients from the CPM group (N = 62, 10 missing data) and in 419% from the MP group
(N = 62, four missing data) (p = 0.59).
The change in the MSFC z scores (CMP: -0.8 vs. MP: -0.5, p = 0.33) and its components at
two years did not differ between groups. The proportion of relapse-free patients was 736% in
the CPM group compared to 561% in the MP group (p = 007), but the follow-up duration dif-
fered between groups.
Adverse events
A similar proportion of patients in the two treatment groups had adverse events (CPM: 972%
versus MP: 924%), most of which were mild to moderate in severity (Tables 3 and 4). A simi-
lar proportion of patients in the two treatment groups had adverse events (CPM: 972% versus
MP: 924%, p = 0.20), most of which were mild to moderate in severity (Tables 3 and 4). The
proportion of serious adverse events was not different between the two groups (CPM: 22.2%
vs. MP: 19.7%, p = 0.72)
Discussion
After 25 years the conversion rate of patients with relapsing-onset MS towards SPMS
approaches 70% [30]. Although this clinical phenotype is associated with severe disability,
there are still few therapeutic options [13]. Disease-modifying therapies used in RRMS have
Table 3. Adverse events, PROMESS trial, France.
System organ class CPM (n = 72) MP (n = 66)
Number of AE Number (%) of patients with
AE
Number of AE Number (%) of patients with
AE
All pooled system organ classes 617 70 (97.2) 409 61 (92.4)
Gastrointestinal disorders 280 59 (81.9) 71 28 (42.4)
Infections and infestations 129 42 (58.3) 109 38 (57.6)
Nervous system disorders 68 34 (47.2) 78 38 (57.6)
General disorders and administration site
conditions
30 23 (31.9) 33 22 (33.3)
Musculoskeletal and connective tissue disorders 17 14 (19.4) 21 12 (18.2)
Skin and subcutaneous tissue disorders 18 15 (20.8) 17 11 (16.7)
Investigations 13 10 (13.9) 15 10 (15.2)
Injury, poisoning and procedural complications 16 12 (16.7) 10 10 (15.2)
Psychiatric disorders 9 8 (11.1) 8 7 (10.6)
Other 37 30 (41.7) 47 34 (51.5)
CPM = Cyclophosphamide; MP = Methylprednisolone; AE = Adverse Events
doi:10.1371/journal.pone.0168834.t003
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usually no or little efficacy in PMS. There is, therefore, a need for new therapeutic options in
SPMS. The mechanisms underlying disability in SPMS associates both inflammation and neu-
rodegeneration. It is generally accepted that the inflammatory component is more important
at the early stages of SPMS which are, therefore, probably, more accessible to immunosuppres-
sive therapy [13]. The population selected for the PROMESS trial is characteristic of early
SPMS with a recent onset of the SPMS phase and relapses present in more than 30% of patients
in the previous year.
The statistical analysis was performed using an intention-to-treat strategy. The primary
analysis using a Cox model did not show a statistically significant superiority of CPM in com-
parison with MP for preventing sustained EDSS progression in the 138 included patients. This
recruitment was inferior to what was planned and a high proportion of patients stopped treat-
ment and follow-up early, more frequently in the CPM group. To take into account the possi-
bility that patient drop-outs precluding the assessment of the primary outcome may result in
informative censoring threatening the validity of the Cox model, a multistate model analysis
was conducted. This alternative analysis concluded that patients in the CPM group were signif-
icantly more likely to stop treatment, but also that those going on their treatment had signifi-
cantly less EDSS progression. This may be interpreted as a possible indication of the efficacy of
CPM in patients who were able to tolerate and continue their CPM treatment. There was also
a trend in favour of CPM when examining the proportion of patients with sustained disability
progression and the proportion of relapse-free patients at two years.
The primary analysis using a Cox model showed a not statistically significant reduction in
the incidence of progression in the CPM group (HR = 061). The results of the Cox model are
difficult to interpret because the trial was underpowered, and because a high proportion of
patients stopped their follow-up before two years with this proportion being much higher in
the CPM group. In survival analysis those patients are censored at the time of discontinuation
of follow-up, but this analysis is valid only as long as censoring is non informative [26]. In the
case when missing data are not completely at random, especially when they are related to the
primary outcome with a proportion of censored patients different in the two groups, results of
the Cox model may be biased. Here, missing data were often related to early discontinuation
of treatment and the inability to convince patients to come to follow-up visits thereafter. To
consider that discontinuation of follow-up was completely at random, i.e. independent from
the risk of disability progression is a strong assumption which was impossible to check. The
main reason for treatment discontinuation was low tolerability which explains that the drop-
out rate was superior to those usually observed in some PMS trials but not all [31]. Among
other causes of discontinuation no specific reason emerged. In particular, no other therapeutic
trial was conducted at the same time.
Because of the high number of treatment discontinuations, a secondary analysis was
planned (before database freeze and treatment unblinding) using a multistate model that
Table 4. Serious adverse events.
Group CPM (n = 72) MP (n = 66)
Serious
Adverse
Events (n)
Sudden death of probable cardio-vascular origin (1)Malignancies
(2): one ovarian and one breast cancer, both occurred during the
first year of treatment
Pericarditis (1)Psychotic episode (1) Rash (1) Hospitalization for
surgery (2) Thrombophlebitis (1)Osteonecrosis (1)Infections (2)
Fractures (2)Hyperglycemia (1)Extravasation (1)
Myocardial infarction (1)Pulmonary embolism (1)Pneumonia (1)
Seizure (1) Pancreatitis (1) Fever (1) Suicide attempt (1)Fractures
(2) Wound (1) Surgery (1)Miscellaneous (2)
CPM = Cyclophosphamide; MP = Methylprednisolone;
doi:10.1371/journal.pone.0168834.t004
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could estimate the hazard of transition to disability progression in both randomization groups
while taking into account at the same time the possible transition to early discontinuation of
treatment. Hence, as indicated by ITT principles, all patients were analysed in their randomi-
zation group, although the transition toward disability progression was estimated only in a
patient subgroup, those who did not discontinue treatment. All sensitivity analyses with differ-
ent multistate models and statistical packages found a significant effect of CPM in delaying dis-
ability progression compared to MP. The non-significant result from the Cox model may be
explained by the limited power of the trial due to the recruitment of less than half of the
planned sample size and the number of censored observations.
Although the use of CPM has been proposed for MS since 1966 [16] and the first study was
performed in 1967 [32], very few RCT examining the efficacy of CPM in PMS have been per-
formed. In an uncontrolled, open-label trial in 86 patients with PMS, stabilization of the dis-
ease was reported for 1–5 years after a short course of CPM in 69% of cases [33]. In the first
RCT, 58 patients with PMS were randomized to receive either a 2–3 week course of IV CPM
to achieve a leucopoenia combined with adrenocorticotrophic hormone (ACTH), or ACTH
alone, or plasma exchange with ACTH and oral CPM [17]. Positive results were reported, as
16 out of 20 patients in the CPM group improved or stabilized at 48 weeks, which was superior
to other groups. The results were not confirmed by a small study in which CPM was compared
to folic acid, used as a placebo [21], or by a double-blind RCT [19]. Limited sample sizes, inad-
equate inclusion criteria, the absence of blinding procedures and a lack of maintenance ther-
apy may explain these inconsistent results.
An open-label study compared 261 patients with PMS who were randomized to receive
either one induction treatment followed by a booster every two months over a two-year period
or no pulse therapy [20]. A significant benefit, although modest, was found in the patients
receiving booster therapy. The results were better in younger patients and patients with recent
progression onset.
In the present trial, we selected patients with less than four years of progression, a recent
documented worsening of disability, and a reduced walking distance in the past year. It is likely
that the treatment of inflammation is more relevant in the early stages of SPMS than in later
stages. However, taking into account relapses in the previous year did not influence the results.
It is difficult to compare the effect size of the treatment with CPM in SPMS with other
drugs than MP. Rituximab and Ocrelizumab have not been tested in SPMS. The population of
the mitoxantrone study15 was very different with only 50% of patients with SPMS and with a
very slow progression even in the placebo group (22% deteriorating over 2 years). Simvastatin
has shown a positive effect on brain atrophy in phase 2 trial in SPMS [34]. A phase 3 trial is
needed to study its efficacy on clinical outcome. The IVIG trial did not show positive results in
the SPMS subgroup [31].
The safety profile was as expected. Besides digestive side effects CPM was generally well tol-
erated. Some serious adverse events were reported in the two groups but were relatively bal-
anced. We did not observe an increase in infections and severe infections in the CPM group,
or haematological or bladder malignancies. A risk of bladder cancer has been reported with
high accumulative doses [35], but not at the dosages used in MS [36]. However the duration of
the study was probably too short to reliably assess this risk. Microscopic haematuria occurred
in four patients with CPM and one with MP, but no symptomatic haemorrhagic cystitis
occurred. The only difference between the two groups concerning side effects was seen in the
gastrointestinal system, with 48 patients having nausea and 31 patients experiencing vomiting
in the CPM group compared to 19 and three in the MP group. This low gastric tolerability,
despite the use of ondansetron, explains the higher drop-out rate observed in the CPM group.
These digestive adverse events are a clear limitation for CPM use but could be overcome by
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using more powerful new anti-emetic agents like aprepitant [37]. The safety profile of CPM
seems better than the safety profile of mitoxantrone, which exposes to cardiac toxicity and leu-
kaemia [38].
One limitation of the study is its limited power, due to a low rate of inclusions. This low
inclusion rate could be explained, at least in part, by the fact that the two study drugs were
available and used in many centres in France, without the need to bear the constraints related
to the participation in a clinical trial. However, during the trial, participating centres proposed
systematically to eligible patients to participate to the study. The baseline characteristics of the
patients (age, EDSS, MSFC z score) which are very similar to a recent sample of SPMS patients
enrolled in a therapeutic trial [33] do not suggest that this has biased significantly the recruit-
ment of the study. Moreover blinding and randomisation contributed to a bias-free selection
of patients included in the study and a good internal validity. The relatively high number of
treatment discontinuation highlights the difficulty of running SPMS trials. In a controlled trial
of IV immunoglobulin against placebo in PMS, the high number of treatment discontinuation
in SPMS patients make difficult the interpretation of the results [31].
One possible limitation of the study is that digestive side effects may have precluded the
correct blinding of the patients. However, all patients included were informed that both drugs
may or may not induce this type of side effect, and all evaluations were performed by a blinded
neurologist who was unaware of the side effects possibly reported by the patients to their treat-
ing neurologist. The two groups differed according to the use of ondansetron in the CPM
group. Although ondansetron, which is a 5HT3 antagonist, has been proposed to treat cerebel-
lar tremor [39], its efficacy has never been confirmed and an effect on neurological disability
in MS is very unlikely.
Another possible limitation is the use of MP as a comparator. As mentioned above,
although placebo-controlled studies are certainly better for demonstrating treatment effi-
cacy, MP IV pulse therapy was proposed as an active comparator after the results of a phase
II trial comparing high-dose IV MP (500mg) to low doses (10mg) every 8 weeks [22]. The
primary end-point of this study was negative (a binomial comparison of proportions of sus-
tained treatment failures on a composite outcome at 2 years) but a treatment effect was
observed according to a comparison of time to onset of sustained progression of disability.
A recent study of pulse oral MP failed to show an effect on intrathecal inflammation in
PMS [40].
In spite of these limitations, although the primary endpoint was negative, the PROMESS
study represents the best available evidence to date that IV pulses of CPM may offer a delay in
disability progression for patients in the first years of SPMS, at least for those who are able to
receive the entire two-year treatment. Using new, more potent antiemetic drugs may allow a
longer treatment with CPM, possibly resulting in improved efficacy for patients. Aggressive
immunosuppression is an option for a subgroup of patients in SPMS, which remains to be
characterized, but has overall only limited efficacy in progressive MS.
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